Showing posts with label pharmaceutical. Show all posts
Showing posts with label pharmaceutical. Show all posts

Monday, 11 September 2017

Branding Science: Where Variety is the Spice of Market Reasearch





An English graduate, a human biology graduate and a business graduate walk into a bar… no this isn’t the start of a terrible joke. This is a tale about how Branding Science’s newest cohort of graduates met, at a Branding Science assessment centre hosted in a pub nearby to the beautiful riverside offices in Wandsworth. So how did such a motley crew from such different paths in education all end up at Branding Science? I will speak on behalf of my fellow grads, Ahmed and Vanessa, when I say that we did not grow up with fanciful dreams of working for a pharmaceuticals market research agency. It was not until after leaving university that we began to consider the existence of this profession.

Vanessa stumbled across pharma market research whilst working for a healthcare communications company, following completion of her masters in pharmaceuticals sciences. Ahmed wanted to take the data analysis and literature skills that he had developed during his PhD in English literature and exercise them in a commercial context and, with a family in healthcare, Branding Science seemed like a great fit. I landed in a consumer insights facility for a global pharma company during a year in industry as part of my business management degree, fell in love with market research and decided to take the small leap from consumer health to pharmaceuticals to indulge in my interest in medicine some more.

Perhaps to the untrained eye there is not an intuitive connection between the worlds of marketing and pharmaceuticals. You might think that in pharma the science speaks for itself, the right medications will get to the people who need them, guided by the healthcare professional’s rational decision making and the functional power of the product. Conversely, in the flash creative world of marketing we imagine a desperate dash to upsell more products at higher prices and increase profit. But this disconnect is a misconception based on false assumptions. Allocating optimal medications to the patients who need them is not as simple as one might like to think. Healthcare professionals are irrational, because human beings are irrational. We all make strange decisions from time to time. The ‘why did I eat that?’ ‘Why did I buy that?’ irrationality that plagues us all also plagues doctors in their prescribing behaviour. The key to success in pharma is understanding healthcare professionals and key decision makers, what drives their decisions and how you can tailor your approach to best meet theirs and patients’ needs. That’s where the marketing comes in: Branding Science can help to develop solutions to overcome the disconnect between patients, prescribers and pharma with a clever repertoire of unique research methodologies to uncover insights which guide our data driven recommendations.

At Branding Science, as new graduates we joined a team with a huge range of backgrounds, skills and experiences, and bring their own wide range of skills to the mix. It is this array of talent and knowledge that has shaped our methodologies, market understanding and understanding of people. Medicine, psychology, philosophy, business, neuroscience…we’ve got the lot! 

 It’s the diversity within the Branding Science team which helps us to deliver superior market research that is carefully tailored to meet our clients’ business needs. 

Whether it’s quantitative or qualitative, strategic or exploratory, concept testing or gaining an understanding of the market landscape, every research project is different and we have the right team to do the job.


If you’re interested in finding out more about our holistic approach to market research please contact
info@branding-science.com. 

Monday, 21 August 2017

How un-focusing doctors can lead to better brand insights




Scrolling through my LinkedIn on a Monday morning (instead of reading emails), I found an article in the Harvard Business review on the brain’s ability to focus*.

The article talked about how focus is a key driver of success, which shouldn’t come as a surprise to anyone. CEOs become CEOs because they are incredibly skilled at focusing on what tasks are vital to a company’s bottom line, whilst the rest of us are powerless to resist a good Buzzfeed article when we should be working.  

The article’s real insight was that, contrary to popular belief, being un-focused is just as vital to our functioning. So vital, that psychologists have given it a technical name: The Default Mode Network.


What is the Default Mode Network (DMN)?

The DMN is what happens when our brain isn’t focusing on and assessing the outside world. It’s when our minds have retreated to the safety and wonder of daydreaming, or when we are feeling particularly sentimental and wish to remember the good times from the past.

This sounds a lot like procrastination - putting off tasks that need to get done - and not at all conducive to decision-making.

However, research has shown that the DMN is heavily involved in activating old memories, going back and forth between the past, present, and future, and recombining different ideas, which is a key component of creativity. When psychologists first examined this neural network within the brain, they saw that it was deactivated during most goal-orientated tasks. But on closer inspection, they saw that this was not the case when those goal-orientated tasks were associated with social interaction and working memory.

With this in mind, it feels as though we might be missing out on the opportunity to use the DMN to help us obtain greater insights from our respondents taking part in market research.

How can we change our approach to gathering insights based on the DMN?

A lot of market research tasks used in interviews place great emphasis on engaging doctors, keeping them focused and making sure their minds don’t wander. This is because we want to download their knowledge in the 60 minutes we have with them, in order to identify how a brand might better communicate to their customers and encourage prescribing.

But what if we did the opposite, and allowed our doctors to become unfocused, activating their DMN?

We might then see the less rational, more emotional responses we seek. It may also help our doctors to be more creative and help us uncover solutions for how to make their brand(s) more compelling than their competitors. By activating the DMN we can better understand the impact of new drugs in the market, and how their behaviour might change as a result.

This is a topic that Brand Garage – our innovation think tank at Branding Science – are currently looking at. Our aim is to design tasks that activate the Default Mode Network, so we can approach our client’s business questions from a wide range of angles. Ultimately providing them with valid solutions as to how to optimise their brand’s marketing strategic.

Watch this space!

For more information about our approaches to helping your brand, email us at: info@branding-science.com 



Monday, 10 July 2017

Motivated Branding … ‘Am I bovvered?’

In a recent New Scientist article, Dan Jones examined some of the startling phenomena of recent political times, most obviously the shock of Brexit/Trump votes and the ‘post truth’ politics underlying these events.

Jones observes that it is in the nature of human beings to think in biased ways. He quotes a study conducted by Dan Kahan at Yale University, which shows that amongst conservatives it is the most scientifically literate who are the strongest deniers of climate change. The phenomenon here is ‘motivated reasoning’ … people interpret facts to fit what they already think or feel. Thus, during these recent campaigns, we see the emergence of facts and ‘alternative facts’ that play to both the hearts and minds of different political tribes.

Kahan’s team conclude that only those fuelled by a genuine scientific curiosity that is more powerful than their competing motivations are capable of rising above opposing claims and making a more objective assessment.

However we are not seeing a new age in which facts no longer matter. When presented with objective facts, people will interpret them subjectively to decide if it is relevant and whether or not it matters to them. In practice, ‘motivated branding’ is the golden goose of many marketers, and finding the underlying keys that will unlock motivation is the ultimate goal of market research.

We have long known the importance of the emotive in either reinforcing or changing the direction of human behaviour. What cognitive neuroscience has now shown [on an MRI] is that emotion and reason are always fellow travellers in human decision making. On occasions, the impact of the emotive can be challenged by those who claim a special exemption for medicine, and objectivity rules because science, and scientists, are governed by different principles that rise above the biases of voters or shoppers and strives towards scientific rigour and objectivity.

In practice though, medicine is done by human beings to human beings and so is also subject to how human beings are. When new treatments are adopted into guidelines [or not] on the basis of the status and passion of their advocates, or when a patients’ treatment is upgraded on the basis of their ‘social worth’, we see a system in operation where the ‘emotive’ does count.

At Branding Science we understand that the task of market research is to determine how best to speak to or challenge human behaviour and build brands that are relevant to the audience and make them care. We need to have hard evidence in our story, but we also need to make it emotionally resonant:



And so ‘motivated branding’ should be the watchword of new treatments and new campaigns. It is not that the emotive is somehow a substitute for rational scientific evidence, but rather it should be a partner to it. Therefore we work with our clients to answer the ‘does this matter to me?’ question in the affirmative.

Email us at info@branding-science.com to talk to us about making your brands matter

This blog was written by Jon Chandler, Senior Director at Branding Science

Wednesday, 5 April 2017

Bad habits, take a hike!


How market research can get to the heart of a habit and help change customer behaviour

The dreaded habit. We all know what they are and we all have our own, and whilst some may be positive everyone will definitely be able to say which habit, or habits (!) they would like to eradicate.

But I have a secret for you: habits cannot be destroyed.

Don’t lose hope though. There are ways to alter those pesky habits that strike at the heart of your good intentions.

Science has shown that habits are stored in the brain, and as we now know, the brain can be re-programmed. Which means whilst they cannot be destroyed, changing a habit is possible.

Firstly, you have to understand a habit. In Charles Duhigg’s book ‘The Power of Habits’ he shows that habits have 3 core components:


In order to change a habit, Duhigg postulates, you have to identify the routine (that’s the behaviour, for example walking to the food point to steal a biscuit). Next, experiment with rewards to find out what’s driving the habit (are you going to the food point because you want to satiate your hunger?), and also isolate the cue (is it hunger pains you’re experiencing?).

Working with Brand Teams within Pharmaceutical companies, we often get asked to help our clients understand why their customers (Physicians, including GPs, specialists, pharmacists) prescribe a product over theirs, even though their drug has ‘better data’, and how they can change such behaviours.

What they’re essentially asking us is: How can we change our customers’ habits?

Well, that is where market research comes in.

We work with physicians, asking them to describe their prescribing practice (the routine), why they prescribe a particular product (the cue) and what outcome they are looking to achieve (the reward). We can do this by having in-depth conversations with physicians, either individually or in a group, or map these behaviours out through online surveys, looking at perceptions of drugs and patient numbers.

As a result, we provide our clients with direction on how to change prescribing behaviours, by giving physicians new cues and rewards that lead them to alter their original habits, helping our clients to position themselves as the brand of choice.

So as you can see, there is hope for you quitting sugar and eating healthy yet! You just need to work out how much you want those cookies, or if there is some other reason you are craving them, and how to break that routine!

Email us at info@branding-science.com to find out more about how Branding Science can help you understand and change your customers’ habits.

Monday, 30 November 2015

The latest pharmaceutical disease: what it is and how to cure it

Having written my MSc dissertation on the future of the pharmaceutical business model, I could type for days on end and have you scrolling forever. However, I don’t think that would ever be published as a blog article. To realise that childhood dream of mine for at least the length of this post…
Come into my office, take a seat and let Dr. Lok tell you something:

The traditional business model of the pharmaceutical sector is failing.

It is a disease that if left untreated, will cause the company that has contracted it to perish. Symptoms include diminishing market share, increasing overheads and a thinning profit margin. The only cure is an innovative business model - no longer a one size fits all approach but one that each pharmaceutical company can mould around themselves. Think of a memory foam mattress; sold the same to all but embracing the individual and supporting their sleeping positions.
Outside of this GP surgery in the real world, we see traditions diminish as technology and other breakthroughs move the next generation forward into another era. This idea can be projected onto the pharmaceutical industry:

The main reason why the traditional business model is failing is due to the increasing difficulty to establish blockbuster drugs, and the growing number of patent cliffs that are drawing ever closer and giving way to a new generation of generics.


By looking at the fundamental management model of patterns of strategic change (Johnson and Scholes, 1993) (above), we can see that the industry has seemingly enjoyed continual growth for a prolonged period of time. Firms now face a period of flux unless they are able to successfully employ a transformative breakout strategy. With such a strategy, firms do not only have a chance to be a formidable competitor in the market, but can transform the business model of the sector as a whole.

The usual go-to for a breakout strategy in many industries is mergers and acquisitions (M&A), but it is no secret that these have not been successful for many in the pharmaceutical industry unless they have been planned strategically. Pfizer for example, was described by the New York Times as “Frankenstein’s monster” in 2012. They had carried out five large M&A deals in the decade preceding 2011, and ended up making substantial losses across the company.

To those suffering from traditional business model disease, I write a prescription for market research.

Market research is key in enabling pharma to understand how they might leverage their brand’s brands’ USPs to protect and even continue to grow their market share in the face of ever increasing generic competition. These USPs can no longer be molecular and data focussed but need to be humanistic. We doctors see patients - people - who are experiencing a dis-ease. By fully understanding these experiences, companies can recognise the value in easing the distress of a patient rather than just focusing on the molecular microbiology or clinical data story.

At Branding Science, we are able to gain a real insight into the rational, but moreover the emotional drivers which spur the prescription of different drugs. From pre-launch to post-launch, we use a variety of innovative psychology-based methods that allow us to dive deep into the thoughts of health care professionals when making prescription decisions. By helping our clients understand the reasoning behind the decisions being made, we are able to work with clients to effectively identify which themes they should leverage their brand upon in order to connect emotionally with both physicians and patients. Therefore, branded drugs can still be at an advantage in terms of maximising market share as long as they remember that their brand is an intangible asset that only they can exploit.


Traditional Business Model Disease does not have to be terminal - the cure however may be unique for each and will be found through the understanding of customers and end users. I look forward to seeing which pharmaceutical company will be first to unlock that cure and transform the industry.

The Author: Chloe Lok is research executive at Branding Science. She holds a Masters in Management from the Imperial college in London and a Bsc in biochemistry from the University of Reading.

Monday, 21 July 2014

Edible Tech


We’ve heard about the innovative ways that healthcare is infiltrating the digital world. Technologies such as mobile aps and techy wristbands have been part of the mainstream healthcare conversation for a while now. However Proteus Digital Health have gone one step further and have developed a new type of ‘edible’ tech.
This miniscule wireless device is actually ingested by the user and feedbacks their bodily vitals to an external computing device. The contraption, which resembles a grain of rice and is made almost entirely of silicon, passes through the body over a space of about a week and feeds back information to the user including heart rate, body temperature, activity levels and rest patterns.

What may be the purpose of receiving such information?
For patient’s friends and families, it is a way to ensure that their loved ones are taking their medications, sleeping correctly and getting enough exercise. And through a clever linking system, the family can send reminders or gentle ‘nudges’ to encourage a healthy lifestyle or compliance to medications. Not only may the information be used to aid adherence to both drugs and lifestyle changes, but it also empowers the patient to be more in control of their illness and especially may help to ease the patient back into society after a stint in hospital, by providing a reassuring edge.
Perhaps more importantly though, the information can also be used by physicians to help monitor their patients. The data can be used to help identify ‘at-risk’ patients who may be more likely to require medical help and even recognise those who need to be admitted to hospital rather than waiting for an appointment and allowing their problem to escalate.

What may be the value of ‘edible tech’ for pharmaceutical companies?
Digital health is something pharmaceutical companies are increasingly engaging in. Both Otsuka and Novartis have announced partnerships with Proteus Digital Health. Novartis, in particular, are looking to use the ingestible device to help with adherence relating to organ transplantation; a therapy area where they have a substantial portfolio.

Yet could this captivating new device be used by ourselves within the realms of market research? Perhaps in patient research this could be a way to truly understand adherence to both medications and lifestyle changes, and match up what respondents believe and say they are doing with clinical data showing their real behaviours. A couple of ideas Branding Science have had include monitoring sleep cycles of patients with insomnia or the exercise patterns of type II diabetic patients. However with Proteus yet to announce a launch date, there is plenty of time to work out more ways to include edible tech in market research.

Thursday, 3 April 2014


Brains, Brands and Sushi: Why Pharma need to focus on the emotive sell.

 
I read a startling statistic the other day that 95% of Brands launched actually fail.

Even more startling was the statistic that two thirds of drugs launched by the pharmaceutical industry fail to meet market impact expectations. Considering there are set to be 400 new drugs released in the next three years this is slightly worrying. Do the math. That’s around 266 potentially lifesaving drugs that will just fade into market obscurity…

So what on earth is going wrong?

Well, to answer that I guess we need to understand why those 5% of Brands that don’t fail, succeed.

It’s so easy to assume people will buy your product simply because you created it and it’s available.

It is also easy for the pharmaceutical industry to assume that customers will select their product for first line use because it happens to have the best clinical data out there. Wrong again. Let’s consider a scenario in the rheumatoid arthritis market where there is a clear market leader despite the fact that competitors also have comparable and in some cases, superior efficacy data. If we can’t explain a product’s use on rational reasons alone then there must be a less rational component.

And we often tell our pharmaceutical clients not to sell a product.

A product is functional. No-one loves toothpaste. They do, however, love Colgate because it promises to give them whiter teeth and fresher breath. And who wouldn’t want both of these things? This is the power of branding.

To understand why this love for Colgate over toothpaste is happening, let’s examine the brain. Because I don’t know if you are aware of this, but the brain controls everything we do. It’s the source of the majority of our behaviour and even though we are light years away from understanding exactly how it works, we have good enough technology at the moment to hazard a guess as to what might be going on.

You’re obviously objecting to my outlandish claim that you “love” Colgate.

But how outlandish is it really?

Using functional magnetic resonance imaging (fMRI) we can study the correlation between behaviour and increased activity in brain areas. By increased activity, I mean the assumption that more activity requires more energy therefore more oxygen is needed. It’s an indirect measure and requires extensive statistical analysis to make any sort of assumption. But for all intents and purposes, it’s a good place to start brain gazing.

So what’s happening when people view their favourite brands?

A study by Esch et al (2012) showed that the palladium (the part of the brain involved in emotional cognition) was positively correlated with viewing familiar brands. Translation: when we view brands we are familiar with, the emotional processing parts of our brain are activated. Moreover, when we view unfamiliar brands, the areas associated with linguistic encoding are comparably more active. Translation: whilst we use emotions to store and retrieve brand perceptions, we use our rational minds to evaluate novel brands.
 

What’s the relevance of this for the pharmaceutical industry?

Well, quite simply, customers are not solely evaluating brands on a rational basis. They aren’t weighing up the pros and cons every time they consider Colgate. The same way doctors aren’t weighing up the efficacy data every single time they prescribe treatments for an RA patient. Through positive experiences with the market leader they have developed a strong emotional attachment to the brand. So when it comes to writing a brand on that prescription letter, it is nearly always their favourite, and more importantly, it is rarely thought about.

What does storing brand perceptions in this way offer the individual?

There has long been a theory that brands might actually function as reward stimuli (Schaefer & Rotte, 2006). And when we do look at brand logos, studies have shown that brain activity increases in the essential component of the brain’s Reward Pathway: The striatum. It receives input from the Cerebral cortex and its outputs get fed into the basal ganglia system that is responsible for a variety of behaviours such as routine behaviours or ‘habits’ and cognition and emotions. Therefore, brand logos are enough to elicit a reward response that feeds into our perception of what we feel the brand offers us.

Furthermore, there is less activity in the brain areas associated with rational choice.

So if you are still with me after all this brain talk, then you’ll be starting to realise that perhaps there’s more to branding than simply conveying the overall benefits of a product.

And that engaging customers might be about more than just describing those benefits.

As our associate director, Anthony Rowbottom, likes to say: “If pharma tried to sell sushi they would describe it as cold, dead fish. That’s exactly what it is. But no-one is going to respond positively to that message.”


Pharma must stop thinking about their customers as cold, clinical doctors and stop selling their products as molecules and impersonal data. They need to appeal to the human in the white coat through the real life patient sat in their surgery opposite them, by describing how their product is providing a practical and emotional benefit for them both.

Think about this next time you are brushing your teeth…

This article was written by Sofia Fionda, Research Executive at Branding Science
To discuss this article follow us on twitter!
 
http://link.springer.com/article/10.1007/s11002-012-9176-3#page-1
http://www.upol.cz/fileadmin/user_upload/FF-katedry/kae/2007_Schaefer_Favorite_Brands_as_Cultural_Objects_Modulate_Reward_Circuit.pdf?origin=publicationDetail


 

 

Thursday, 27 March 2014


Accidental Blockbusters: Warfarin





“Of course, that’s how life is. A turn of events may seem very small at the time it’s happening, but you never really know, do you?” Tom Xavier

Warfarin is an anticoagulant currently prescribed to prevent blood clots. However it was originally introduced to the consumer world as a rat poison due to its haemorrhaging abilities.

In the early 1920’s a bizarre number of cattle in the US kept spontaneously bleeding profusely. Food sources in the area were scarce and so the cattle were being left to eat the damp, mouldy hay that was no good to anyone else. A Canadian vet twigged that the link between all of these haemorrhaging cattle was that they had consumed this unsuitable hay, and discovered that by removing the hay from the cattle’s diet, they returned to full health.

Thirty years later, the compound in the mouldy hay was finally characterised and was launched into the US market as a rat poison, proving an instant success. However a US soldier, unsuccessfully, tried to commit suicide by overdosing on this new toxin. Having been rushed to hospital, he was treated with vitamin K, the antidote, and made a full recovery, yet this started an investigation into the potential therapeutic use of the poison. And three years later, it was approved for use as an anticoagulant, with one of its first recipients being the US president at the time; Dwight D. Eisenhower.

One conspiracy theory, highlighting the dangers of warfarin and the complexity of its dosing regimen, suggests that Stalin was murdered using warfarin. As warfarin is tasteless and odourless, making it such a good rat poison, Stalin could have easily consumed it without knowing so, and he exhibited many of the symptoms commonly found in a warfarin overdose when he died.



This post was written by Graduate Research Exec Becky Geffen.
For more weird and wonderful pharamcetuical facts follow us on: @brandingscience